Nothing Special   »   [go: up one dir, main page]

PE20190108A1 - Moleculas de anticuerpo para el tratamiento del cancer - Google Patents

Moleculas de anticuerpo para el tratamiento del cancer

Info

Publication number
PE20190108A1
PE20190108A1 PE2018002814A PE2018002814A PE20190108A1 PE 20190108 A1 PE20190108 A1 PE 20190108A1 PE 2018002814 A PE2018002814 A PE 2018002814A PE 2018002814 A PE2018002814 A PE 2018002814A PE 20190108 A1 PE20190108 A1 PE 20190108A1
Authority
PE
Peru
Prior art keywords
seq
antibody molecules
cancer
treatment
sequence
Prior art date
Application number
PE2018002814A
Other languages
English (en)
Inventor
Markus Zettl
Ivo Lorenz
Otmar Schaaf
Melanie Wurm
Jean-François Fortin
Scott Brodeur
Keith A Canada
Lukasz Chlewicki
Walter Carroll Davidson
Pankaj Gupta
Priyanka Gupta
Rocio K Perez
Jr Joseph Robert Woska
Haiguang Xiao
Danlin Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20190108A1 publication Critical patent/PE20190108A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a moleculas de anticuerpo anti-PD1 (proteina de muerte celular programada 1) que comprende: (a) CRD de la cadena pesada que comprenden la secuencias SEQ ID NO: 1 (hcCDR1), SEQ ID NO: 2 (hcCDR2) y SEQ ID NO: 3 (hcCDR3) y tiene CDR de la secuencia liviana que comprenden la secuencia SEQ ID NO: 4 (lcCDR1), SEQ ID NO: 5 (lcCDR2) y SEQ ID NO: 6 (lcCDR3); entre otros. Tambien se refiere a acidos nucleicos que codifican dichas moleculas de anticuerpo; celulas huesped que expresan o son capaces de expresar dichas moleculas de anticuerpo; composiciones que comprenden dichas moleculas de anticuerpo y tambien comprenden anticuerpos anti-LAG3 (gen 3 de activacion de linfocitos); siendo utiles para el tratamiento del cancer
PE2018002814A 2016-05-18 2017-05-17 Moleculas de anticuerpo para el tratamiento del cancer PE20190108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16170174 2016-05-18

Publications (1)

Publication Number Publication Date
PE20190108A1 true PE20190108A1 (es) 2019-01-15

Family

ID=56014918

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002814A PE20190108A1 (es) 2016-05-18 2017-05-17 Moleculas de anticuerpo para el tratamiento del cancer

Country Status (31)

Country Link
US (3) US11028169B2 (es)
EP (2) EP3458478B1 (es)
JP (3) JP6585860B2 (es)
KR (2) KR102419412B1 (es)
CN (2) CN115340608A (es)
AR (1) AR108516A1 (es)
AU (1) AU2017266298B2 (es)
BR (1) BR112018072986A2 (es)
CA (1) CA3020649A1 (es)
CL (2) CL2018003153A1 (es)
CO (1) CO2018012374A2 (es)
CY (1) CY1123977T1 (es)
DK (1) DK3458478T3 (es)
EA (1) EA201892616A1 (es)
ES (1) ES2857813T3 (es)
HU (1) HUE053452T2 (es)
IL (1) IL262892B2 (es)
LT (1) LT3458478T (es)
MA (2) MA55697A (es)
MX (2) MX2018014102A (es)
MY (1) MY193112A (es)
PE (1) PE20190108A1 (es)
PH (1) PH12018502429A1 (es)
PL (1) PL3458478T3 (es)
RS (1) RS61510B1 (es)
SA (1) SA518400424B1 (es)
SG (1) SG11201809627QA (es)
SI (1) SI3458478T1 (es)
TW (2) TWI762484B (es)
UA (1) UA127200C2 (es)
WO (1) WO2017198741A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3377531A2 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CA3020649A1 (en) 2016-05-18 2017-11-23 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
CN110062766B (zh) 2016-10-13 2023-12-15 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
DK3541841T3 (da) 2016-11-18 2024-10-21 Servier Lab Anti-PD-1-antistoffer og sammensætninger
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MA46814B2 (fr) 2017-02-10 2022-09-30 Regeneron Pharma Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
BR112019021032A2 (pt) * 2017-04-05 2020-05-05 Boehringer Ingelheim Int terapia combinada anticâncer
PE20191741A1 (es) * 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
KR20240146108A (ko) 2017-05-30 2024-10-07 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
KR20200013231A (ko) * 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
WO2019120269A1 (zh) * 2017-12-22 2019-06-27 江苏恒瑞医药股份有限公司 Lag-3抗体药物组合物及其用途
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHODS FOR THE TREATMENT OF CANCER OR AN INFECTION USING A COMBINATION OF AN ANTI-PD -1 ANTIBODY, AN ANTI-LAG3 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
US12090142B2 (en) * 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
CA3096705A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP2021527082A (ja) * 2018-06-11 2021-10-11 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 新規な免疫チェックポイント阻害剤
CN112739371A (zh) * 2018-07-26 2021-04-30 百时美施贵宝公司 用于治疗癌症的lag-3组合疗法
MX2021003903A (es) 2018-10-19 2021-06-04 Bristol Myers Squibb Co Terapia combinada para el melanoma.
WO2020096917A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
US20210380694A1 (en) 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112021008873A8 (pt) * 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
EP3946617A1 (en) * 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy
SG11202111262XA (en) * 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2022532930A (ja) 2019-05-23 2022-07-20 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
EP3983450A4 (en) * 2019-06-12 2023-07-05 Nanjing GenScript Biotech Co., Ltd. ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE
CN112121169B (zh) * 2019-06-24 2023-10-24 广州再极医药科技有限公司 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JPWO2021025140A1 (es) 2019-08-08 2021-02-11
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
KR20220066334A (ko) 2019-09-22 2022-05-24 브리스톨-마이어스 스큅 컴퍼니 Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
US20220411499A1 (en) 2019-11-08 2022-12-29 Bristol-Myers Squibb Company LAG-3 Antagonist Therapy for Melanoma
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
TW202210499A (zh) 2020-06-03 2022-03-16 德商百靈佳殷格翰國際股份有限公司 編碼CD80胞外域Fc融合蛋白之重組桿形病毒
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
IL301533A (en) 2020-09-24 2023-05-01 Merck Sharp ַ& Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2023548051A (ja) 2020-10-23 2023-11-15 ブリストル－マイヤーズ スクイブ カンパニー 肺がんのためのｌａｇ－３アンタゴニスト療法
CA3200671A1 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR20240005700A (ko) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
US20240327544A1 (en) 2021-07-13 2024-10-03 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
WO2023183317A2 (en) * 2022-03-21 2023-09-28 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
IL316628A (en) 2022-05-12 2024-12-01 Genmab As Binding agents capable of binding to CD27 in combination therapy
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
AU2023305094A1 (en) 2022-07-15 2025-01-16 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024153768A1 (en) 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DK0703925T3 (da) 1993-06-03 1999-12-06 Therapeutic Antibodies Inc Fremstilling af antistoffragmenter
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
PL364623A1 (en) 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2855521A4 (en) 2012-05-24 2016-03-02 Mountgate Group Ltd COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
PL2970464T3 (pl) * 2013-03-15 2020-10-05 Glaxosmithkline Intellectual Property Development Limited Wiążące białka anty-lag-3
MX2015015037A (es) * 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
FI3508502T3 (fi) * 2013-09-20 2023-06-06 Bristol Myers Squibb Co Anti-lag-3-vasta-aineiden ja anti-pd-1-vasta-aineiden yhdistelmä kasvainten hoitamiseksi
JP6535337B2 (ja) * 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
WO2015085847A1 (zh) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2015138920A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2956471A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN107743401B (zh) 2015-04-17 2021-08-24 百时美施贵宝公司 包含抗pd-1抗体和另外的抗体的组合的组合物
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CA3020649A1 (en) 2016-05-18 2017-11-23 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment

Also Published As

Publication number Publication date
CN109415439A (zh) 2019-03-01
JP2020007340A (ja) 2020-01-16
CL2021002094A1 (es) 2022-04-08
DK3458478T3 (da) 2021-03-22
CA3020649A1 (en) 2017-11-23
MX2022008184A (es) 2022-08-02
TW202307002A (zh) 2023-02-16
JP6585860B2 (ja) 2019-10-02
AU2017266298B2 (en) 2024-01-04
CY1123977T1 (el) 2022-05-27
BR112018072986A2 (pt) 2019-03-06
TWI762484B (zh) 2022-05-01
IL262892B1 (en) 2023-12-01
TW201806974A (zh) 2018-03-01
IL262892A (en) 2018-12-31
EP3848393A1 (en) 2021-07-14
MX2018014102A (es) 2019-04-29
RS61510B1 (sr) 2021-03-31
IL262892B2 (en) 2024-04-01
MA45029B1 (fr) 2021-03-31
LT3458478T (lt) 2021-02-10
PL3458478T3 (pl) 2021-06-28
AU2017266298A1 (en) 2018-10-25
AR108516A1 (es) 2018-08-29
SI3458478T1 (sl) 2021-04-30
KR20220103806A (ko) 2022-07-22
US20210095020A1 (en) 2021-04-01
CO2018012374A2 (es) 2018-11-30
CL2018003153A1 (es) 2019-01-18
US20170334995A1 (en) 2017-11-23
MA55697A (fr) 2022-02-23
SG11201809627QA (en) 2018-12-28
JP2019522460A (ja) 2019-08-15
US11028169B2 (en) 2021-06-08
EA201892616A1 (ru) 2019-05-31
ES2857813T3 (es) 2021-09-29
WO2017198741A1 (en) 2017-11-23
JP6585801B2 (ja) 2019-10-02
EP3458478B1 (en) 2021-01-06
US11795219B2 (en) 2023-10-24
EP3458478A1 (en) 2019-03-27
UA127200C2 (uk) 2023-06-07
KR102419412B1 (ko) 2022-07-12
CN109415439B (zh) 2022-10-04
HUE053452T2 (hu) 2021-07-28
CN115340608A (zh) 2022-11-15
JP2019050804A (ja) 2019-04-04
US20240124581A1 (en) 2024-04-18
MY193112A (en) 2022-09-26
SA518400424B1 (ar) 2022-08-17
KR20190006177A (ko) 2019-01-17
PH12018502429A1 (en) 2019-09-30
MA45029A (fr) 2019-03-27

Similar Documents

Publication Publication Date Title
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
SA519401370B1 (ar) الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1)
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
UY36539A (es) Proteínas de unión a icos
MX2019005116A (es) Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
CO6761352A2 (es) Anticuerpos neutralizadores anti-ccl20
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
NZ741080A (en) Anti-lag3 antibodies and uses thereof
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
AR080663A1 (es) Proteinas de union especificas y sus usos
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CU20180129A7 (es) Anticuerpos anti-basigin humanizados
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
AR126091A2 (es) Anticuerpo o fragmento de unión al antígeno de este, molécula de adn, vector de clonación o expresión y célula hospedadora
CO2019006926A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
EA201992136A1 (ru) Антитела против pd-l1
AR106940A1 (es) Anticuerpos anti claudina y métodos de uso
AR102872A1 (es) Anticuerpos anti-pd-1 y sus métodos de uso